Trial Profile
A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Rifampin, and Quinidine on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2022
Price :
$35
*
At a glance
- Drugs Zelicapavir (Primary) ; Itraconazole; Quinidine; Rifampicin
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Enanta Pharmaceuticals
- 12 Jun 2019 Status changed from recruiting to completed.
- 05 Dec 2018 New trial record